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ier Taiwan LLC. Open access under CSummary Background: In Taiwan, the prevalence of colorectal cancer has been increasing in
recent decades. As a result, the fecal occult blood test (FOBT) has been advocated and widely
used for colorectal cancer screening in areas with limited colonoscopy capacity. The goal of
this study was to analyze the sensitivity of a single immunochemical FOBT (I-FOBT) and corre-
late it with the results of colonoscopy for detecting colorectal neoplasia in the asymptomatic
Taiwanese population.
Methods: Data were collected from the results of health examinations conducted on asymp-
tomatic adults older than 40 years and who simultaneously underwent one-time I-FOBT and co-
lonoscopy examinations between January 01, 2008 and June 30, 2009. The sensitivity and
specificity of the I-FOBT were calculated in correlation to age, size, and pathologic result.
Results: A total of 6096 patients were analyzed, including 3418men and 2678women, aged 40e87
years. I-FOBT result was positive in 229 patients (3.8%); the sensitivity of detection of total colo-
rectal neoplasia and advanced neoplasia were 6.98% and 22.1%, respectively. A total of 13 partic-
ipants were found to have invasive cancer in this study, and the sensitivity and specificity of the
I-FOBT in this group were 69.2% and 96.4%, respectively. Besides, the positive rate of I-FOBTt of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Number 5, Fu-Sing Street,
33, Taiwan.
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Immunochemical FOBT for detection of colorectal neoplasms 75increasedwith age,with 40e49 years (2.89%), 50e75 years (4.21%), and>75 years (5.68%). In addi-
tion, the sensitivity for detecting total neoplasia and advanced neoplasia was similar in patients
50 years and 40 years of age.
Conclusion: The I-FOBT has better sensitivity for detecting invasive cancer and advanced
neoplasia than for detecting nonadvanced neoplasia. Repeated I-FOBT examinations with good
adherence to the screening programmay improve the detection rate and sensitivity of the I-FOBT.
Copyrightª 2014, The Gastroenterological Society of Taiwan and TheDigestive Endoscopy Society
of Taiwan. Published by Elsevier Taiwan LLC. Open access under CC BY-NC-ND license.Introduction
Colorectal cancer is a major public health issue due to its
increasing prevalence and mortality in developed coun-
tries, and also in Taiwan. According to the statistics of the
Department of Health (Taiwan), the age-standardized
incidence of colorectal cancer has progressively risen over
the past 20 years, from 1990 (17.10 per 100,000 in men and
14.73 per 100,000 in women) to 2009 (48.65 per 100,000 in
men and 34.48 per 100,000 in women). Most cases of
colorectal cancer are found sporadically, and the morbidity
and mortality can be reduced with improvement in the
early detection of precancerous lesions or of early-stage
cancer. Therefore, a fecal occult blood test (FOBT) for
adults aged 50e69 years, every 2 years, has been promoted
by the Bureau of Health Promotion in Taiwan.
The guaiac fecal occult blood test (G-FOBT) for the
screening and early detection of colorectal cancer was
found to reduce the risks of mortality [1]. However, the
conventional G-FOBT was shown to have a low sensitivity
for colorectal cancer and advanced colonic polyps. As this
test is not specific for human hemoglobin, some foods or
medications may induce false-positive or false-negative
results [2,3]. Diet restrictions are, therefore, needed
prior to conducting a G-FOBT. Several studies have sug-
gested that the immunochemical fecal occult blood test (I-
FOBT) has better sensitivity than the conventional G-FOBT
[4e6]. The I-FOBT makes use of antibodies specific to
human hemoglobin, eliminating the necessity for dietary
restrictions. In this study, we analyzed the sensitivity of a
one-time, qualitative, I-FOBT for detecting colorectal
neoplasia in asymptomatic population of different age
groups.Materials and methods
The study was designed to analyze retrospectively an
asymptomatic population that underwent a health exami-
nation at the Health Care Center of Chang Gung Memorial
Hospital (Guieshan, Taiwan). A total of 8258 nonhospital-
ized persons were consecutively enrolled between January
2008 and June 2009, after having undergone a simultaneous
one-time, qualitative I-FOBT and a colonoscopy examina-
tion. We excluded 1584 participants, younger than 40
years, due to a lower prevalence of colonic neoplasia in this
age group, according to a previous study [7]. Furthermore,
578 patients were excluded due to incomplete or missing
information, the presence of established colorectal canceror inflammatory bowel disease, visible rectal bleeding, or
menstruation during the time of stool specimen collection.
Therefore, 6096 participants were included in our analyses.Fecal sampling
A one-time I-FOBT was performed for each participant. The
participants received an explanation and instructions for
preparing the fecal sample from a stool specimen, along
with collection kits. They were asked to write their name
and the date of collection on the tube. Stool specimens
were self-collected, using a sampling probe (Eiken Chemi-
cal, Tokyo, Japan) by scraping different areas of the stool
specimen’s surface. The probe was then firmly reinserted
into the tube and sealed. The collection kit was brought to
the clinic on the day of the colonoscopy. The kits were sent
to the laboratory for testing within 24 hours. The sample
was processed using the OC-LIGHT system (Eiken Chemical).
The fecal sample was diluted with sodium azide-containing
buffer to stabilize the hemoglobin and then reacted with
the antibody on the test strip. A positive result was indi-
cated by the presence of blue lines on the test strip, with a
detection range from 10 mg/g to 100 mg/g of feces. The
sensitivity was 50 ng Hb/mL of buffer or 10 mg/g of feces.Colonoscopy
Each participant was provided with 2 L of polyethylene
glycerol electrolyte solution (1-day standard program) or
two doses (45 mL each) oral sodium phosphate solution (2-
day standard program) for bowel preparation at home.
They were also instructed to eat a low-fiber diet or a clear
liquid diet for 3 days prior to the colonoscopy. Incomplete
studies or individuals improperly prepared were excluded
from the study. Experienced endoscopists performed the
colonoscopy and were blinded to the results of the I-FOBTs.
All the neoplasms identified by colonoscopy were recorded
by the endoscopists, but the largest or most advanced
lesion was recorded in this study. Polyps <0.5 cm were
removed using cold biopsy forceps. However, if a larger
lesion (0.5 cm) was found, removal was performed by
polypectomy or endoscopic mucosal resection. If invasive
cancer was suspected, biopsy would be done for tissue
proof first before further management. Patients who un-
derwent a biopsy, polypectomy, or endoscopic mucosal
resection were referred to the outpatient department for
further management.
Table 1 Characteristics of the study population.
Characteristic Number of patients (%)
Eligible (n Z 6096)
Sex
Male 3418 (56.1)
Female 2678 (43.9)
Age (y)
Range 40e87
Mean  SD 53.65  8.42
40e49 2214 (36.3)
50e75 3794 (62.2)
>75 88 (1.5)
I-FOBT
Positive 229 (3.8)
Negative 5867 (96.2)
Colonoscopy findings
No neoplasia 4620 (75.8)
Tubular adenoma <10 mm 1222 (20.0)
Advanced neoplasia
Tubular adenoma 10 mm 80 (1.3)
Adenoma with villous
component
145 (2.4)
High-grade dysplasia 16 (0.3)
Invasive cancer 13 (0.2)
Total 254 (4.2)
Size of neoplasia Mean lesion size  SD (mm)
No neoplasia 1.04  1.68
Tubular adenoma <10 mm 4.14  1.56
Advanced neoplasia
Tubular adenoma 10 mm 12.8  4.96
Adenoma with villous
component
9.74  5.63
High-grade dysplasia 15.0  8.29
Invasive cancer 34.6  18.2
I-FOBT Z immunochemical fecal occult blood test;
SD Z standard deviation.
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Each specimen collected for biopsy or polypectomy was
fixed in formaldehyde and sent for a pathological assess-
ment. The pathologists were also blinded to the results of
the I-FOBT. Histological characteristics of the polyps were
recorded as the absence of neoplasia (including hyper-
plastic polyps), tubular adenoma (TA) <10 mm,
TA  10 mm, adenoma with a villous component, high-
grade dysplasia, or invasive cancer. Advanced neoplasia
was defined as TA  10 mm, adenoma with a villous
component, high-grade dysplasia, or invasive cancer.
Statistical analysis
We calculated the sensitivity and specificity of the I-FOBTs
for detecting colorectal neoplasia, advanced neoplasia,
and invasive cancer, on the basis of endoscopic and path-
ologic findings of colonoscopy. In different age groups, the
sensitivity, specificity, positive predictive values, and
negative predictive values were also calculated. SPSS Sta-
tistics software version 17.0 (IBM Inc., Armonk, NY, USA)
was applied for statistical analyses.
Results
Of the 8258 participants who enrolled, 2162 were excluded,
leaving a total of 6096 adults (3418 men and 2678 women)
for the analyses. The mean age of the patients was
53.65  8.42 years (range, 40e87.0 years). Different age
groups of participants were classified and analyzed,
including those aged 40e49 years (2214 participants,
36.3%), 50e75 years (3794 participants, 62.2%), and >75
years (88 participants, 1.5%). No serious colonoscopy com-
plications were recorded. The I-FOBT was positive in 229
participants (3.8%) and negative in 5867 (96.2%). Table 1
shows the basic characteristics of all the eligible partici-
pants; no significant differences were observed for each
characteristic. As per the results of colonoscopy, no evi-
dence of neoplasia was found in 4620 participants (75.8%),
and TAs (<10 mm) were found in 1222 patients (24.2%).
Advanced neoplasia was found in 254 patients, including TA
(10 mm) in 80 patients (1.3%), adenoma with a villous
component in 145 patients (2.4%), high-grade dysplasia in
16 patients (0.3%), and invasive cancer in 13 patients
(0.2%). The size of the colonic neoplasia was also recorded,
according to the results of colonoscopy and pathological
findings.
In Table 2, characteristics of the colonic neoplasms and
the diagnostic performance of the I-FOBTs are shown.
Positive I-FOBTs were found in 47 (out of 1222) patients
with TAs (<10 mm), with a sensitivity of 3.85%. However,
the sensitivity of the I-FOBT in the group with advanced
neoplasia increased to 22.1%, and up to 69.2% when inva-
sive cancer was detected. However, four cases of invasive
cancer were not detected by the I-FOBT. The overall
sensitivity for detecting colorectal neoplasia was 6.98%. By
contrast, out of 229 patients with positive I-FOBT results,
neoplastic lesions were found in 103 patients (45.0%) and
advanced neoplasia was found in 56 patients (24.5%). In I-
FOBT-negative patients, 23.4% demonstrated neoplasia(1373 of 5867), with only 3.4% having advanced neoplasia
(198 of 5867). An increased risk of neoplasia was found in
the group with positive I-FOBT results compared to the
group with negative I-FOBT results, with a relative risk of
1.92. The same result was also found in the group with
advanced neoplasia, in patients with positive I-FOBT re-
sults; the relative risk was 7.25 compared with patients
with negative I-FOBT results. For colorectal neoplasia and
advanced neoplasia, the rates of false-positive results were
2.73% and 2.96%, and that of false-negative results were
93.0% and 78.0%, respectively. The positive and negative
predictive values of total colorectal neoplasia (45.0%,
76.6%) and advanced neoplasia (24.5%, 96.6%) were also
analyzed.
Table 3 shows the I-FOBT results and colonoscopy find-
ings in patients stratified by age categories. The percentage
of advanced neoplasia among all colorectal neoplasia
increased with age: 14.7% (56/380) in those aged 40e49
years, 18.0% (192/1069) among 50e75-year olds, and 22.2%
(6/27) in individuals aged >75 years. The positive rate,
sensitivity for total neoplasia, and positive predictive value
of I-FOBT also increased with age. Increased I-FOBT
Table 2 Diagnostic performance of I-FOBT and correlation of colonoscopy results.
Colonoscopy findings I-FOBT Total (%) Sensitivity (%) (95% CI) Specificity (%) (95% CI)
Negative (%) Positive (%)
No neoplasia 4494 (76.6) 126 (55.0) 4620 (75.8)
Total neoplasia 1373 (23.4) 103 (45.0) 1476 (24.2) 6.98 (5.68e8.28) 97.3 (96.8e97.7)
Tubular adenoma <10 mm 1175 (20.0) 47 (20.5) 1222 (20.0) 3.85 (2.77e4.92) 96.3 (95.7e96.8)
Advanced neoplasia
Tubular adenoma 10 mm 69 (1.2) 11 (4.8) 80 (1.3) 13.8 (6.2e21.3) 96.4 (95.9e96.9)
Adenoma with villous component 114 (1.9) 31 (13.5) 145 (2.4) 21.4 (14.7e28.1) 96.7 (96.2e97.1)
High-grade dysplasia 11 (0.2) 5 (2.2) 16 (0.3) 31.3 (8.54e54.0) 96.3 (95.8e96.8)
Invasive cancer 4 (0.1) 9 (3.9) 13 (0.2) 69.2 (44.1e94.3) 96.4 (95.9e96.9)
Total 198 (3.4) 56 (24.5) 254 (4.2) 22.1 (17.0e27.2) 97.0 (96.6e97.5)
Total 5867 229 6096
CI Z confidence interval; I-FOBT Z immunochemical fecal occult blood test.
Table 3 Results of colonoscopy and I-FOBT in different age groups.
Age group
40e49 y 50e75 y >75 y 50 y 40 y
No neoplasia 39/1834 85/2725 2/61 87/2786 126/4620
Tubular adenoma <10 mm 7/324 39/877 1/21 40/898 47/1222
Advanced neoplasia
Tubular adenoma 10 mm 5/17 6/61 0/2 6/63 11/80
Adenoma with villous component 9/30 22/113 0/2 22/115 31/145
High-grade dysplasia 1/4 2/10 2/2 4/12 5/16
Invasive cancer 3/5 6/8 0/0 6/8 9/13
Total 18/56 36/192 2/6 38/198 56/254
Total 64/2214 160/3794 5/88 165/3882 229/6096
I-FOBT positive rate (%) 2.89 4.21 5.68 4.25 3.76
Sensitivity of total
neoplasia (%) (95% CI)
6.58 (4.1e9.1) 7.02 (5.48e8.55) 11.1 (0e23.0) 7.12 (5.59e8.64) 6.98 (5.68e8.28)
Sensitivity of advanced
neoplasia (%) (95% CI)
32.1 (19.9e44.4) 18.8 (13.2e24.3) 33.3 (0e71.1) 19.2 (13.7e24.7) 22.0 (17.0e27.2)
Positive predictive value for
advanced neoplasia (%) (95% CI)
28.1 (17.1e39.1) 22.5 (16.0e29.0) 40.0 (0e82.9) 23.0 (16.6e29.5) 24.5 (18.9e30.0)
CI Z confidence interval; I-FOBT Z immunochemical fecal occult blood test.
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neoplasia, was also found in each age group. Invasive can-
cer was detected in the age groups of 40e49 years and
50e75 years, with a total of 13 patients found to have
invasive disease. In the subdivided groups of patients 40
years of age, the sensitivity for detecting advanced
neoplasia (22.0%) and the positive predictive values (24.5%)
were similar to those of the subdivided groups of age 50
years (19.2% and 23.0%, respectively).Discussion
Recent treatment guidelines have recommended that
annual I-FOBTs replace annual G-FOBTs for colorectal can-
cer screening [8]. This examination for cancer screening is
easy and feasible, and several studies have shown that its
sensitivity for colorectal neoplasm ranges from 56% to 91%
and specificity from 88.2% to 97% [7,9e13]. Other studies
have also compared the I-FOBT with colonoscopy in thegeneral population [7,14]. Previous studies reported that
the I-FOBT has improved sensitivity for detecting colorectal
cancer and advanced adenomatous polyps compared to
guaiac-based occult blood test [9,15e19]. In addition, the I-
FOBT is less affected by food, eliminating the need for di-
etary restrictions prior to the test. In Taiwan, the FOBT has
been advocated by the Bureau of Health Promotion for in-
dividuals over 50 years of age. Here, we examined the
prevalence of colorectal neoplasia and the detection of
advanced colonic neoplasia by using the I-FOBT, among
patients in different age groups, which may affect clinical
decision making and screening strategies.
In this study, a qualitative I-FOBT, based on immuno-
chromatographic technology, was used to evaluate stool
occult blood, with a sensitivity of 50 ng Hb/mL. A similar
study evaluated the qualitative FOBT method in 5841 par-
ticipants [20]. However, that study evaluated only distal
colonic lesions by sigmoidoscopy rather than by colonos-
copy. The sensitivity for distal advanced neoplasms was
33.1%. Our study revealed that the sensitivity of the one-
78 Y.-Y. Chen et al.time I-FOBT was 6.98% for total colorectal neoplasia and
22.1% for advanced neoplasia; the specificities were 97.3%
and 97.0%, respectively. The sensitivity for the detection of
invasive cancer was 69.2%, with 96.4% specificity. Although
the sensitivity and specificity of FOBT may be affected by
the cut-off values used, our results were similar to those
found in a previous, large-scale study involving 21,805
asymptomatic adults where a quantitative FOBT was
used [7].
The sensitivity of the I-FOBT was 6.98% (103/1476) for
total colorectal neoplasia, 22.1% (56/254) for advanced
neoplasia, and 69.2% (9/13) for invasive cancer, with
increasing sensitivity being associated with advanced
pathological grades, which may be helpful for cancer
screening. Similar results were also found in previous
studies [7,14]. Early detection of advanced neoplasia is
important for the early management of colorectal neo-
plasms. Hofstad et al [21] found that one-fourth of the
patients with adenomas <10 mm have a tendency for net
growth, and patients with multiple adenomas have more
new polyps than those with a single adenoma. Clark et al
[22] also reported the results from an autopsy series that
showed that only 2.5/1000 polyps per year progress to
cancer, and Ransohoff [23] stated that large adenomas
progress to cancer at a rate of approximately 1% per year.
Other studies have also shown that annual or biennial FOBTs
[24,25] can reduce the mortality of colorectal cancer.
Therefore, although the sensitivity of the I-FOBT was low in
this study, repeated I-FOBTs may be beneficial for cancer
screening and early management, to avoid the progression
of colonic neoplasia.
Moreover, we found that the proportion of advanced
neoplasms may be associated with age, as shown in Table 3.
Since health examination is increasingly universal in
Taiwan, and also increasing number of middle-aged people
paid attention and joined the examinations, so we sub-
divided our study population into three age groups (40e49,
50e75 and S75) and tried to analyze the differences
between age categories. The positive rate of the I-FOBT
and its sensitivity for total neoplasia were found to have
similar correlations to age. Most colon cancers are generally
accepted to have originated from previous adenomas. The
prevalence rates for both adenomatous polyps and cancer
increase with age, and previous studies have shown that, as
age distribution curves have revealed, adenomas may be
followed by carcinomas within 5e10 years [26,27]. There-
fore, an early detection of colorectal malignancy or
advanced neoplasia has been emphasized. Our participants
were also stratified into two age categories, those 50
years and those 40 years, for additional analyses in order
to assess the effect of starting screening 10 years earlier
than the age recommended by the Bureau of Health Pro-
motion in Taiwan. The sensitivity of detection of total
neoplasia in these 2 groups did not differ significantly (50
years: 7.12%, 40 years: 6.98%), as did the detection of
advanced neoplasia in these 2 age groups (50 years:
19.2%, 40 years: 22.0%). The American College of
Gastroenterology-recommended age for starting colorectal
cancer annual screening is also 50 years among individuals
with an average risk and 45 years for African Americans [8].
Furthermore, the literature supports the notion that ciga-
rette smoking and obesity are associated with an increasedrisk of colorectal cancer at an earlier age, which is also
mentioned in the American College of Gastroenterology
guidelines [8]. Therefore, earlier screening, beginning at an
age of 40 years, with the I-FOBT may be considered, at
least in members of the population at higher risk, such as
those who are heavy smokers, obese, or have a family
history of colon cancer or related neoplasia. Further study
is needed to determine the age and the population at
increased risk for beginning I-FOBT.
Our study had several limitations. First, small polyps
may be missed due to the accuracy limits of colonoscopy,
even when performed by an experienced endoscopist. This
may result in an underestimation of the prevalence of
colonic neoplasia. Second, this was a retrospective study
and selection bias may be a defect of the population under
study. Besides, the sensitivity and positive predictive values
decreased in the age group of 50e75 years, which may be
affected by the heterogeneous study population with
mixture of different risk groups, including first-time
screening or received prior surveillance of colorectal neo-
plasms. Third, first-screening and surveillance patients
could not be distinguished due to a lack of clinical infor-
mation, which may restrict the external validity and
applicability of the study results to the general population.
Fourth, the 1-day method of I-FOBT may reduce the
sensitivity for the detection of small adenomatous polyps or
other advanced neoplasia. However, the use of the 2- or 3-
day method may probably increase both the sensitivity and
the rate of false positives, as well as minimize the
compliance of the participants involved in the health ex-
amination. Therefore, a single examination of the I-FOBT
could not exclude negative screening of colorectal
neoplasia. By contrast, different cut-off values of the I-
FOBT may also affect the screening result. No consensus or
randomized study has been made that the adequate cut-off
value of I-FOBT, except one large-scale study in 2007 with
assessment of the cost-effectiveness of I-FOBT and identi-
fied 110 ng/mL as the optimal cut-off [28]. Lastly, we did
not possess other clinical information for further evaluation
of the participants, such as family history, dietary habits,
etc. These types of data would have provided additional
information for evaluation and helped avoid selection bias.
In conclusion, we demonstrated the sensitivity of a one-
time I-FOBT for detecting advanced colonic neoplasia in a
retrospective study involving asymptomatic individuals
from Taiwan. Although the sensitivity was relatively low,
similar to those in previous studies, repeated studies may
be beneficial for the early management of advanced
colonic neoplasia and colorectal cancer, helping to mini-
mize morbidity and mortality. Besides, receiving the I-FOBT
at an earlier age (40 years) may also be beneficial for the
early detection of advanced colorectal neoplasms. Our
study may promote further research on the I-FOBT and
early detection of colonic neoplasia, including assessment
of the cost effectiveness of I-FOBT for different age cate-
gories and risk groups in Taiwan, and may clarify the un-
resolved issues and improve our national health policy.Conflicts of interest
All authors declare no conflicts of interest.
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